Clarion Medical Technologies has entered into an agreement to distribute Verisante Technology's Verisante Aura in Canada.
Aura is a non-invasive optical system which uses Raman spectroscopy to biochemically analyze the skin and provide immediate results.
Verisante Aura is indicated for use for the evaluation of skin lesions that may be clinically suspicious for melanoma, squamous cell carcinoma or basal cell carcinoma.
Verisante Aura is used by medical professional to obtain additional information to rule skin lesions conditions before making a final decision to biopsy.
Clarion CEO Dan Webb said clinical study results have shown that Verisante Aura has the potential to revolutionize the way skin cancer is diagnosed.